Platelet hyperactivation in maintained growth hormone-deficient childhood patients after therapy withdrawal as a putative earlier marker of increased cardiovascular risk

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 1, 2005, Pages 98-105

  Reis, Flávio ^a   Campos, Maria Vitor ^a,b   Bastos, Margarida ^b   Almeida, Luis ^a   Lourenço, Margarida ^b   Ferrer Antunes, Carlos A ^b   Palmeiro, Aida ^b   Santos Dias, José D ^a   Mesquita, José F ^a   Carvalheiro, Manuela ^b   Teixeira, Frederico ^a,c  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATECHOLAMINE BLOOD LEVEL; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; FEMALE; GROWTH HORMONE DEFICIENCY; HUMAN; MALE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TREATMENT WITHDRAWAL;

ADULT; BIOLOGICAL MARKERS; BLOOD PLATELETS; CALCIUM; CARDIOVASCULAR DISEASES; CATECHOLAMINES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMAN GROWTH HORMONE; HUMANS; MALE; PLATELET ACTIVATION; PLATELET AGGREGATION; RISK;

EID: 19944427824     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-0477     Document Type: Article

References (52)

1. Rosén T, Bengtsson B-A 1990 Premature mortality due to cardiovascular diseases in hypopituitarism. Lancet 336:285-288
2. Bulow B, Hagmar L, Mikoczy Z, Nordstrom CH, Erfurth EM 1997 Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 46:75-81
3. Carrol PV, Christ ER, Bengtsson B-A, Carlsson L, Christiansen JS, Clemmons D, Hintz R, Ho K, Laron Z, Sizonenko P, Sonksen PH, Tanaka T, Thorner M 1998 Growth hormone deficiency in adulthood and effect of growth hormone replacement: a review. J Clin Endocrinol Metab 83:382-395
4. Barretto-Filho JA, Alcantara MR, Salvatori R, Barretto MA, Sousa AC, Bastos V, Souza AH, Pereira RM, Clayton PE, Gill MS, Aguiar-Oliveira MH 2002 Familial isolated growth hormone deficiency is associated with increased systolic blood pressure, central obesity, and dyslipidemia. J Clin Endocrinol Metab 87:2018-2023
5. Colao A, Di Somma C, Pivonello R, Cuocolo A, Spinelli L, Bonaduce D, Salvatore M, Lombardi G 2002 The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study. J Clin Endocrinol Metab 87:1088-1093
6. Besson A, Salemi S, Gallati S, Jenal A, Horn R, Mullis PS, Mullis PE 2003 Reduced longevity in untreated patients with isolated growth hormone deficiency. J Clin Endocrinol Metab 88:3664-3667
7. Lehmann ED, Gosling RG 1991 Measurement of aortic distensibility. Lancet 338:1075
8. Sverrisdóttir YB, Elam M, Bengtsson B-A, Johannsson G 1998 Intense sympathetic activity in adults with hypopituitarism and untreated growth hormone deficiency. J Clin Endocrinol Metab 83:1881-1885
9. Scott EM, Greenwood JP, Stoker JB, Mary DASG, Gilbey SG 2002 Sympathetic nerve hyperactivity is associated with increased peripheral vascular resistance in hypopituitary patients with growth hormone deficiency. Clin Endocrinol (Oxf) 56:759-763
10. Bengtsson B-A, Johannsson G 1999 Effect of growth hormone therapy on early atherosclerotic changes in GH-deficient patients. Lancet 353:1898-1899
11. Capaldo B, Patti L, Oliviero U, Longobardi S, Pardo F, Vitale F, Fazio S, Di Rella F, Biondi B, Lombardi G, Sacca L 1997 Increased arterial intima-media thickness in childhood-onset growth hormone deficiency. J Clin Endocrinol Metab 82:1378-1381
12. Beshyah SA, Johnston DG 1999 Cardiovascular disease and risk factors in adults with hypopituitarism. Clin Endocrinol (Oxf) 50:1-15
13. Elhadd TA, Abdu TA, Oxtoby J, Kennedy G, McLaren M, Neary R, Belch JJF, Clayton RN 2001 Biochemical and biophysical markers of endothelial dysfunction in adults with hypopituitarism and severe GH deficiency. J Clin Endocrinol Metab 86:4223-4232
14. Jallab RS, Liberman B, Vianna CB, Vieira ML, Ramires JA, Knoepfelmacher M 2003 Effects of growth hormone replacement therapy on metabolic and cardiac parameters in adult patients with childhood-onset growth hormone deficiency. Growth Horm IGF Res 13:81-88
15. Whitehead HM, Boreham C, McIlrath EM, Sheridan B, Kennedy L, Atkinson AB, Hadden DR 1992 Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross-over study. Clin Endocrinol (Oxf) 36:45-52
16. Florkowski CM, Collier GR, Zimmet PZ, Livesey JH, Espiner EA, Donald RA 1996 Low-dose growth hormone replacement lowers plasma leptin and fat stores without affecting body mass index in adults with growth hormone deficiency. Clin Endocrinol (Oxf) 45:769-773
17. Vahl N, Jorgensen JOL, Hansen TB, Klausen IB, Jurik A-G, Hagen C, Christiansen JS 1998 The favourable effects of growth hormone (GH) substitution on hypercholesterolaemia in GH-deficient adults are not associated with concomitant reductions in adiposity. A 12-month placebo-controlled study. Int J Obes 22:529-536
18. Sesmilo G, Biller BMK, Llevadot J, Hayden D, Hanson G, Rifai N, Klibanski A 2000 Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. Ann Intern Med 133:111-122
19. Nicolson A, Toogood AA, Rahim A, Shalet SM 1996 The prevalence of severe growth hormone deficiency in adults who received growth hormone replacement in childhood. Clin Endocrinol (Oxf) 44:311-316
20. ter Maaten JC 2000 Should we start and continue growth hormone (GH) replacement therapy in adults with GH deficiency? Ann Med 32:452-461
21. Leong GM, Johannsson G 2003 Growth hormone deficiency: strategies and indications to continue growth hormone therapy in transition from adolescence to adult life. Horm Res 60:78-85
22. Rahim A, Toogood AA, Shalet SM 1996 The assessment of growth hormone status in normal young adult males using a variety of provocative agents. Clin Endocrinol (Oxf) 45:557-562
23. Clayton PE, Freeth JS, Norman MR 1999 Congenital growth hormone insensitivity syndromes and their relevance to idiopathic short stature. Clin Endocrinol (Oxf) 50:275-283
24. Osorio MGF, Marui S, Jorge AA, Latronico AC, Lo LSS, Leite CC, Esteban V, Mendonca BB, Arnhold IJP 2002 Pituitary magnetic resonance imaging and function in patients with growth hormone deficiency with and without mutations in GHRH-R, GH-1, or PROP-1 genes. J Clin Endocrinol Metab 87:5076-5084
25. Rosenfeld RG, Albertsson-Wikland K, Cassorla F, Frasier SD, Hasegawa Y, Hintz RL, Lafranchi S, Lippe B, Loriaux L, Melmed S, Preece MA, Ranke MB, Reiter EO, Rogol AD, Underwood LE, Werther GA 1995 Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab 80:1532-1539
26. Attanasio AF, Lamberts SWJ, Matranga AMC, Birkett MA, Bates PC, Valk NK, Hilsted J, Bengtsson B-A, Strasburger CJ 1997 Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. J Clin Endocrinol Metab 82:82-88
27. White JG 1994 Platelets and atherosclerosis. Eur J Clin Invest 24:25-29
28. Body SC 1996 Platelet activation and interactions with the microvasculature. J Cardiovasc Pharmacol 27(Suppl 1):S13-S25
29. Pletscher A 1988 Platelets: use and limitations. Experientia 44:152-155
30. i in smooth muscle. Ann Rev Physiol 51:315-329
31. Siess W 1989 Molecular mechanisms of platelet activation. Physiol Rev 69:58-178
32. Wacharasindhu S, Cotterill AM, Camacho-Hübner C, Besser GM, Savage MO 1996 Normal growth hormone secretion in growth hormone insufficient children retested after completion of linear growth. Clin Endocrinol (Oxf) 45:553-556
33. 1998 Consensus guideline for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society on adult growth hormone deficiency. J Clin Endocrinol Metab 83:379-381
34. Reis F, Tavares P, Teixeira F 2000 The distribution of catecholamines between plasma and platelets in cyclosporin A-induced hypertensive rats. Pharmacol Res 4:129-135
35. Reis F, Tavares P, Rito LC, Teixeira HM, Santos-Dias JD, Ferrer-Antunes C, Mesquita JF, Teixeira F 2000 Platelet activation is increased in cyclosporin A-induced hypertensive rats. J Cardiovasc Pharmacol 6:56-64
36. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 260:3440-3450
37. Cardinal DC, Flower RJ 1980 The electronic aggregometer: a novel device for assessing platelet behaviour in blood. J Pharmacol Methods 3:135-158
38. Pfeifer M, Verhovec R, Zizek B, Prezelj J, Poredos P, Clayton RN 1999 Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab 84:453-457
39. Cuneo RC, Salomon F, Watts GF, Hesp R, Sonken PM 1993 Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism 42:1519-1523
40. de Boer H, Blok GJ, Voerman HJ, Phillips M, Schouten JA 1994 Serum lipid levels in growth hormone-deficient men. Metabolism 43:199-203
41. Gleeson HK, Souza AHO, Gill MS, Wieringa GE, Barretto ESA, Barretto-Filho JAS, Shalet SM, Aguiar-Oliveira MH, Clayton PE 2002 Lipid profiles in untreated severe congenital isolated growth hormone deficiency through the lifespan. Clin Endocrinol (Oxf) 57:89-95
42. Vahl N, Klausen I, Christiansen JS, Jorgensen JO 1999 Growth hormone (GH) status is an independent determinant of serum levels of cholesterol and triglycerides in healthy adults. Clin Endocrinol (Oxf) 51:309-316
43. Colao A, Di Somma C, Salerno M, Spinelli L, Orio F, Lombardi G 2002 The cardiovascular risk of adult GH deficiency adolescents. J Clin Endocrinol Metab 87:3650-3655
44. Sas T, Mulder P, Hokken-Koelega A 2000 Body composition, and lipid metabolism before and during long-term growth hormone (GH) treatment in children with short stature born small for gestational age either with or without GH deficiency. J Clin Endocrinol Metab 85:3786-3792
45. Ten Have SM, van der Lely AJ, Lamberts SW 1997 Increase in haemoglobin concentrations in growth hormone deficient adults during recombinant growth hormone replacement therapy. Clin Endocrinol (Oxf) 47:565-570
46. Sartorio A, Cattaneo M, Bucciarelli P, Bottasso B, Porretti S, Epaminonda P, Faglia G, Arosio M 2000 Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly. Exp Clin Endocrinol Diabetes 108:486-492
47. Lanes R, Paoli M, Carrillo E, Villaroel O, Palacios A 2003 Cardiovascular risk of young growth-hormone-deficient adolescents. Differences in growth-hormone-treated and untreated patients. Horm Res 60:291-296
48. Besser GM, Paxton AM, Johnson SAN, Moody EJ, Mortimer CH, Hall R, Gomez-Pan A, Schally AV, Kastin AJ, Coy DH 1975 Impairment of platelet function by growth hormone release-inhibiting hormone. Lancet 24:1166-1168
49. Medina RA, Aranda E, Verdugo C, Kato S, Owen GI 2003 The action of ovarian hormones in cardiovascular disease. Biol Res 36:325-341
50. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M; Women's Health Initiative Investigators 2003 Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349:523-534
51. Porsova-Dutoit I, Sulcova J, Starka L 2000 Do DHEA/DHEAS play a protective role in coronary heart disease? Physiol Res 49:S43-S56
52. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP 2001 Oral contraceptives, hormone replacement therapy and thrombosis. Thromb Haemost 86:112-123